Femara(R) (letrozole) FIRST Aromatase Inhibitor to Indicate Overall Survival Benefit
Femara showed reduced risk of death by 13% (P=0.08) versus tamoxifen, despite inclusion of patients who had switched over from tamoxifen to Femara during the study period, following the study's unblinding
Linear Mode
